Abstract: The present invention relates to a biologically active serum-derived composition of matter (SDF), having a low molecular weight, being electrically charged at acidic pH and having absorption at 280 nm. The molecular weight of said SDF was determined by electron spray mass spectrometry and is of 316 Da. SDF of the present invention or its complex with ceruloplasmin (CP) have several therapeutic properties. For example, SDF or its complex with CP is capable of inducing terminal cell differentiation of leukemic cells, which as a result, may lose their ability to proliferate and their ability for self cell renewal. Further, SDF or the complex with CP is capable of stimulating the proliferation of early, normal progenitor cells and inhibiting enhanced angiogenesis. In addition, SDF or its complex with CP is capable of ex vivo expanding normal stem and progenitor cells.

Abstract: The invention is directed to a peptide, comprising the amino acid sequence substantially as denoted by SEQ ID NO:1 and biologically functional homologues and derivatives thereof.

Abstract: A variety of heparanase specific molecular probes which can be used for research and medical applications including diagnosis and therapy. Specific applications include the use of a heparanase specific molecular probe for detection of the presence, absence or level of heparanase expression; the use of a heparanase specific molecular probe for therapy of a condition associated with expression of heparanase; the use of a heparanase specific molecular probe for quantification of heparanase in a body fluid; the use of a heparanase specific molecular probe for targeted drug delivery; and the use of a heparanase specific molecular probe as a therapeutic agent.

Abstract: A variety of heparanase specific molecular probes which can be used for research and medical applications including diagnosis and therapy. Specific applications include the use of a heparanase specific molecular probe for detection of the presence, absence or level of heparanase expression; the use of a heparanase specific molecular probe for therapy of a condition associated with expression of heparanase; the use of a heparanase specific molecular probe for quantification of heparanase in a body fluid; the use of a heparanase specific molecular probe for targeted drug delivery; and the use of a heparanase specific molecular probe as a therapeutic agent.

Abstract: A polynucleotide (hpa) encoding a polypeptide having heparanase activity, vectors including same, genetically modified cells expressing heparanase, a recombinant protein having heparanase activity and antisense oligonucleotides and constructs for modulating heparanase expression.

Abstract: A polynucleotide (hpa) encoding a polypeptide having heparanase activity, vectors including same, genetically modified cells expressing heparanase, a recombinant protein having heparanase activity and antisense oligonucleotides and constructs for modulating heparanase expression are provided.

Abstract: Avian and reptile derived heparanase.

Abstract: A monoclonal antibody elicited by a heparanase protein or an immunogenical portion thereof, the monoclonal antibody specifically inhibits heparanase activity.

Abstract: Radiolabeled epidermal growth factor receptor tyrosine kinase (EGFR-TK) irreversible inhibitors and their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are disclosed.

Abstract: A variety of heparanase specific molecular probes which can be used for research and medical applications including diagnosis and therapy are disclosed. Specific applications include the use of a heparanase specific molecular probe for detection of the presence, absence or level of heparanase expression; the use of a heparanase specific molecular probe for therapy of a condition associated with expression of heparanase; the use of a heparanase specific molecular probe for quantification of heparanase in a body fluid; the use of a heparanase specific molecular probe for targeted drug delivery; and, the use of a heparanase specific molecular probe as a therapeutic agent.

Abstract: The present invention is directed to a substantially pure protein that has cytostatic but not cytotoxic activity. The invention also provides a continuous cell line that produces the protein, and methods for its purification. The invention is also directed towards the use of the inhibitory protein, both in vitro and in vivo, in reducing the proliferation of bone marrow cells and leukocytes, modulating inflammation, as well as in immunosuppression and the treatment of cancer.

Abstract: Radiolabeled epidermal growth factor receptor tyrosine kinase (EGFR-TK) irreversible inhibitors and their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are disclosed.

Abstract: The present invention features a method of inducing donor-specific tolerance in a host. Tolerogenic treatments of the present invention may be administered to a host prior to transplantation of donor-derived materials. The tolerogenic treatment involves (1) administering an immunosuppressive agent to a host mammal in a non-myeloablative regimen sufficient to decrease, but not necessarily to eliminate, the host mammal's functional T lymphocyte population; (2) infusing donor antigens from a non-syngeneic donor into the host mammal; (3) eliminating those host T lymphocytes responding to the infused donor antigens using a non-myeloablative dose of lymphocytotoxic or tolerizing agent; and (4) administering donor hematopoietic cells to the host mammal. Donor lymphoid cells used for cell therapy of a host mammal can be depleted of host specific immunological reactivity by methods essentially similar to those use for tolerizing a host mammal prior to transplantation.

Abstract: The present invention features a method of inducing donor-specific tolerance in a host. Tolerogenic treatments of the present invention may be administered to a host prior to transplantation of donor-derived materials. The tolerogenic treatment involves (1) administering an immunosuppressive agent to a host mammal in a non-myeloablative regimen sufficient to decrease, but not necessarily to eliminate, the host mammal's functional T lymphocyte population; (2) infusing donor antigens from a non-syngeneic donor into the host mammal; (3) eliminating those host T lymphocytes responding to the infused donor antigens using a non-myeloablative dose of lymphocytotoxic or tolerizing agent; and (4) administering donor hematopoietic cells to the host mammal. Donor lymphoid cells used for cell therapy of a host mammal can be depleted of host specific immunological reactivity by methods essentially similar to those use for tolerizing a host mammal prior to transplantation.

Abstract: Methods and compositions for inducing and/or accelerating wound healing and/or angiogenesis via the catalytic activity of heparanase are disclosed.

Abstract: A method for administering the HAV vaccine to a subject by absorption through a mucosal tissue, particularly through the mucosa of the rectum. The method of the present invention enables the HAV vaccine to be administered to the subject rectally, for example as a suppository or other rectal dosage form, and to successfully immunize the subject against HAV. Thus, the present invention overcomes problems of background art methods of administration, such as systemic administration by injection for example, which require needles, and which are difficult and expensive to perform.

Abstract: The present invention provides fibrin microbeads that are biologically active and comprise extensively cross-linked fibrin(ogen) without using glutaraldehyde, and a method for preparing the fibrin microbeads. The present invention also provides a composition comprising cells bound to the fibrin microbeads, and methods for culturing and separating cells using the fibrin microbeads of the present invention. Finally, the present invention provides methods for transplanting cells and engineering tissue using the fibrin microbeads of the present invention.

Abstract: A method of treating a human cancer patient having a solid tumor comprising malignant cells is disclosed, wherein the patient having undergone a cancer therapy regimen comprising allogeneic stem cell transplantation. The method comprises administering allogeneic lymphocytes to the patient and monitoring the patient for levels of malignant cells.

Abstract: A radiolabeled compound of a formula: ##STR1## is described. R1 and R2 are each independently selected from the group consisting of hydrogen, alkyl, hydroxy, alkoxy, halo, haloalkyl, carboxy, carbalkoxy and salts thereof; and A, B, C and D are each independently selected from the group consisting of a hydrogen and an electron withdrawing group, provided that at least one of A, B, C and D is [18]fluorine.

Abstract: Methods have been discovered for treating minimal residual disease following removal of most or a substantial fraction of malignant cells from a cancer patient. An autologous stem cell transplant is performed on the patient. Following partial hematopoiesis recovery, the patient is infused with allogeneic peripheral blood lymphocytes, either alone or in combination with in vivo or in vitro cytokine. The infused allogeneic lymphocytes engender an anti-malignant cell response and can be instrumental in prevention of disease relapse.